|
11-18-2008, 03:51 PM
|
|||
|
|||
EGFR-Targeting Antibody Licensed To Abbott
The international Ludwig Institute for Cancer Research (LICR) has announced that one of its spin-off companies, Life Science Pharmaceuticals, has licensed its lead cancer therapy candidate, antibody 806, to pharmaceutical company Abbott. The 806 antibody targets the EGFR cell surface protein but - crucially - only when the protein is over-expressed (over-produced) in cancer.
You must register in order to see the links 
|
 |
| Thread Tools | |
| Display Modes | |
Similar Threads
|
||||
| Thread | Thread Starter | Forum | Replies | Last Post |
| Oxford Meningococcus Vaccine Licensed To Novartis Vaccines And Diagnostics | Reber | General Health | 0 | 11-07-2008 07:35 AM |
| Seattle Genetics Presents Data On SGN-70, A Humanized Monoclonal Antibody Targeting C | Reber | General Health | 0 | 10-29-2008 07:27 PM |
| Never After - Original Mix by Abbott & Chambers | Reber | Dance | 0 | 08-25-2008 04:43 PM |
| Cold Plasma Technologies With Medical Potential Get Licensed | Reber | General Health | 0 | 07-24-2008 06:47 PM |
| Minnesota Claims Adjuster Licensing - 3 Steps to Become a Licensed MN Insurance Adjus | Reber | General Category | 0 | 07-08-2008 09:07 PM |
Linear Mode
